MALVERN, Pa. & STAFFORD, England--(BUSINESS WIRE)--PuriCore (LSE:PURI), the life sciences company focused on developing and commercializing proprietary solutions that safely, effectively, and naturally kill infectious pathogens, today announced results of a randomized clinical trial showing the potential effectiveness of its Vashe Wound Therapy in the post-operative care of split-thickness skin grafts for burn injuries. Vashe Wound Therapy is a medical device that produces a biocompatible solution to enhance the clinical management of acute and chronic wounds and has been used successfully and without report of adverse events in more than 100,000 wound treatments. It is a safe, effective, and economical alternative to commonly used wound irrigating solutions that inhibit wound healing.
